Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology

Is Parkinson's Disease Genetic or Hereditary?

At a Glance

Most cases of Parkinson's disease (85-90%) are idiopathic and not directly inherited. Only 10-15% of cases are linked to specific inherited genetic mutations, such as LRRK2 or GBA. Even if a genetic mutation is passed down, it does not guarantee the disease will develop.

Most cases of Parkinson’s disease are not strictly hereditary. Approximately 85% to 90% of Parkinson’s cases are idiopathic, meaning they occur sporadically without a known cause or clear family history [1][2]. However, genetics do play a role, and about 10% to 15% of cases are directly linked to specific genetic variations [1]. If you have been diagnosed with idiopathic Parkinson’s, the risk of your children developing the disease is only slightly higher than the general population’s baseline risk, meaning their overall risk remains very low [3].

Idiopathic vs. Genetic Parkinson’s

When researchers study Parkinson’s, they generally divide it into two categories:

  • Idiopathic Parkinson’s Disease: This is the most common form. While first-degree relatives (like children or siblings) have a slightly increased risk of developing the disease compared to someone with no family history [3], there is no single “Parkinson’s gene” passed down that causes it. Instead, it is likely caused by a complex combination of minor genetic risks, age, and broad environmental factors (such as a history of head injury or long-term exposure to certain agricultural pesticides) [3].
  • Genetic (Familial) Parkinson’s Disease: A smaller percentage of cases are caused by inherited genetic mutations [1]. These cases are often associated with a strong family history or early-onset Parkinson’s disease (diagnosed before age 50) [4][5].

Key Genes Associated with Parkinson’s

Researchers have identified several specific genes that are linked to Parkinson’s disease. The most common ones include:

  • LRRK2 (Leucine-rich repeat kinase 2): Mutations in this gene are a prominent genetic risk factor [6]. They are particularly common in people of Ashkenazi Jewish or North African Berber descent [7]. LRRK2 is an autosomal dominant gene, meaning a parent only needs to pass down one copy for their child to inherit the mutation [6]. However, the LRRK2 gene has incomplete penetrance [8]. This means that even if someone inherits the mutated gene, their lifetime risk of actually developing Parkinson’s is often less than 50% [8].
  • GBA (Glucocerebrosidase): This is considered a genetic “risk factor” or susceptibility gene, rather than a direct cause [9]. Like LRRK2, GBA mutations have low penetrance, meaning many people who carry the mutation will never develop the disease [10]. The mutation affects how cells manage waste, which can sometimes encourage the buildup of proteins associated with Parkinson’s [11], but the presence of the gene alone is usually not enough to cause the disease.
  • SNCA (Alpha-synuclein): Although rare, mutations in this gene were the first to be definitively linked to Parkinson’s disease [12]. Like LRRK2, it is an autosomal dominant gene.
  • PRKN (Parkin) and PINK1: These genes are typically associated with early-onset Parkinson’s disease [12][13]. They are autosomal recessive, which means a child must inherit a mutated copy from both parents to develop the disease [12]. If they inherit only one, they are simply a carrier.

What This Means for Your Children

A top concern for parents upon diagnosis is whether they will pass the condition to their kids. The reality depends heavily on the type of Parkinson’s you have:

  • If you have idiopathic Parkinson’s: There is no single genetic mutation to pass down. Your children’s risk is only slightly elevated above the average person’s risk, which means it remains a small possibility, not an expectation [3].
  • If you have an autosomal dominant mutation (like LRRK2 or SNCA): There is a 50% chance you will pass the mutated gene to each child [8][12]. However, because of incomplete penetrance, even if they inherit the gene, their actual risk of developing the disease is lower than 50% [8].
  • If you have an autosomal recessive mutation (like PRKN): You will pass one copy of the gene to your children. Unless your partner also carries a mutation in the exact same gene, your children will be carriers but are very unlikely to develop the disease [1][12].

Should You Consider Genetic Testing?

Understanding your genetic status is becoming increasingly relevant for clinical management. Knowing if you carry a specific mutation might eventually make you eligible for targeted clinical trials [14].

However, before pursuing testing, it is highly recommended that you speak with a genetic counselor [14][15]. Genetic counselors are specially trained professionals who can help you and your family understand inheritance patterns, assess your personal risk, and navigate the emotional and practical implications of genetic testing [14][16]. For example, while the Genetic Information Nondiscrimination Act (GINA) in the United States protects you from health insurance and employment discrimination based on genetic tests, it does not apply to life insurance or long-term care insurance [14]. A counselor will help you weigh these factors before you make a decision.

Common questions in this guide

Is Parkinson's disease passed down from parents to children?
Most cases of Parkinson's are not directly inherited. About 85% to 90% of cases are idiopathic, meaning they happen without a clear family history, though having a parent with Parkinson's does slightly increase your risk compared to the general population.
What is the difference between idiopathic and genetic Parkinson's?
Idiopathic Parkinson's is the most common form and has no single genetic cause. Genetic or familial Parkinson's accounts for 10% to 15% of cases and is directly linked to inherited genetic mutations, often appearing in people diagnosed before age 50.
If I carry a Parkinson's gene mutation, will I definitely get the disease?
Not necessarily. Many genes associated with Parkinson's, such as LRRK2 and GBA, have incomplete penetrance. This means that even if you inherit the mutated gene, your overall lifetime risk of developing the disease is often less than 50%.
Should I get genetic testing for Parkinson's disease?
Knowing your genetic status can help with your clinical management and eligibility for targeted clinical trials. However, you should speak with a genetic counselor first to understand the inheritance patterns and consider how testing might impact things like life insurance.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my age of onset and family history, do you recommend I undergo genetic testing?
  2. 2.If I test positive for a genetic mutation, how might that change my current treatment plan or my eligibility for clinical trials?
  3. 3.Can you refer me to a genetic counselor to discuss the risks and implications for my family before I make a decision about testing?
  4. 4.Are there any specific prodromal (early warning) signs my adult children should look out for, or should they avoid worrying about it unless symptoms appear?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    The Genetics of Parkinson's Disease and Implications for Clinical Practice.

    Day JO, Mullin S

    Genes 2021; (12(7)) doi:10.3390/genes12071006.

    PMID: 34208795
  2. 2

    Genetics of Parkinson's disease.

    Lill CM

    Molecular and cellular probes 2016; (30(6)):386-396 doi:10.1016/j.mcp.2016.11.001.

    PMID: 27818248
  3. 3

    Investigation of non-motor symptoms in first-degree relatives of patients with Parkinson's disease.

    Liu JB, Leng JL, Zhang XJ, et al.

    Parkinsonism & related disorders 2018; (52()):62-68 doi:10.1016/j.parkreldis.2018.03.021.

    PMID: 29606605
  4. 4

    Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study.

    Di Fonzo A, Percetti M, Monfrini E, et al.

    Movement disorders : official journal of the Movement Disorder Society 2023; (38(12)):2241-2248 doi:10.1002/mds.29617.

    PMID: 37750340
  5. 5

    Molecular characterization of PRKN structural variations identified through whole-genome sequencing.

    Bravo P, Darvish H, Tafakhori A, et al.

    Molecular genetics & genomic medicine 2018; (6(6)):1243-1248 doi:10.1002/mgg3.482.

    PMID: 30328284
  6. 6

    Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.

    Lake J, Reed X, Langston RG, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(1)):95-105 doi:10.1002/mds.28787.

    PMID: 34542912
  7. 7

    Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry.

    Cornejo-Olivas M, Torres L, Velit-Salazar MR, et al.

    NPJ Parkinson's disease 2017; (3()):19 doi:10.1038/s41531-017-0020-6.

    PMID: 28649619
  8. 8

    Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF-α Pathway.

    Lin CH, Lin HY, Ho EP, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(4)):745-757 doi:10.1002/mds.28890.

    PMID: 34918781
  9. 9

    Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.

    Schierding W, Farrow S, Fadason T, et al.

    Movement disorders : official journal of the Movement Disorder Society 2020; (35(8)):1346-1356 doi:10.1002/mds.28144.

    PMID: 32557794
  10. 10

    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.

    Avenali M, Cerri S, Ongari G, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(5)):1267-1272 doi:10.1002/mds.28496.

    PMID: 33617695
  11. 11

    LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous GBA1 Expression in Human iPSC-Derived Neurons.

    Sanyal A, Novis HS, Gasser E, et al.

    Frontiers in neuroscience 2020; (14()):442 doi:10.3389/fnins.2020.00442.

    PMID: 32499675
  12. 12

    Cognitive Impairment in Genetic Parkinson's Disease.

    Planas-Ballvé A, Vilas D

    Parkinson's disease 2021; (2021()):8610285 doi:10.1155/2021/8610285.

    PMID: 35003622
  13. 13

    Novel compound heterozygous FBXO7 mutations in a family with early onset Parkinson's disease.

    Lorenzo-Betancor O, Lin YH, Samii A, et al.

    Parkinsonism & related disorders 2020; (80()):142-147 doi:10.1016/j.parkreldis.2020.09.035.

    PMID: 33002721
  14. 14

    Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease.

    Schneider SA, Alcalay RN

    Journal of neurology 2020; (267(3)):860-869 doi:10.1007/s00415-020-09705-7.

    PMID: 31974807
  15. 15

    Tools for communicating risk for Parkinson's disease.

    Cook L, Schulze J, Uhlmann WR, et al.

    NPJ Parkinson's disease 2022; (8(1)):164 doi:10.1038/s41531-022-00432-6.

    PMID: 36446806
  16. 16

    Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.

    Schneider SA, Hizli B, Alcalay RN

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2020; (17(4)):1378-1392 doi:10.1007/s13311-020-00920-8.

    PMID: 32914362

This page explains the genetic factors of Parkinson's disease for educational purposes only. Always consult a neurologist or genetic counselor to understand your specific risks and genetic testing options.

Get notified when new evidence is published on Parkinson's Disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.